Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06401980 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

162

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: Darolutamide
OTHER: Standard of care

Sponsor

Swiss Cancer Institute